ZnT8 Loss of Function Mutation Increases Resistance of Human Embryonic Stem Cell-Derived Beta Cells to Apoptosis in Low Zinc Condition
Open Access
Abstract
The rare SLC30A8 mutation encoding a truncating p.Arg138* variant (R138X) in zinc transporter 8 (ZnT8) is associated with a 65% reduced risk for type 2 diabetes. To determine whether ZnT8 is required for beta cell development and function, we derived human pluripotent stem cells carrying the R138X mutation and differentiated them into insulin-producing cells. We found that human pluripotent stem cells with homozygous or heterozygous R138X mutation and the null (KO) mutation have normal efficiency of differentiation towards insulin-producing cells, but these cells show diffuse granules that lack crystalline zinc-containing insulin granules. Insulin secretion is not compromised in vitro by KO or R138X mutations in human embryonic stem cell-derived beta cells (sc-beta cells). Likewise, the ability of sc-beta cells to secrete insulin and maintain glucose homeostasis after transplantation into mice was comparable across different genotypes. Interestingly, sc-beta cells with the SLC30A8 KO mutation showed increased cytoplasmic zinc, and cells with either KO or R138X mutation were resistant to apoptosis when extracellular zinc was limiting. These findings are consistent with a protective role of zinc in cell death and with the protective role of zinc in T2D.Keywords
Funding Information
- American Diabetes Association (1-16-ICTS-029, NIDDK UC4 DK104207, NIH P30 DK26687-36, R01 DK 057846-16, NIH P30 DK0636-08, WT212625/Z/18/Z, MR/R022259/1)
- Columbia University Diabetes Research Center Pilot and Feasibility (1-16-ICTS-029, NIDDK UC4 DK104207, NIH P30 DK26687-36, R01 DK 057846-16, NIH P30 DK0636-08, WT212625/Z/18/Z, MR/R022259/1)
- Wellcome Trust Investigator award (1-16-ICTS-029, NIDDK UC4 DK104207, NIH P30 DK26687-36, R01 DK 057846-16, NIH P30 DK0636-08, WT212625/Z/18/Z, MR/R022259/1)
- Université de Montréal, and a John R. Evans Leaders Award from Innovation Canada (1-16-ICTS-029, NIDDK UC4 DK104207, NIH P30 DK26687-36, R01 DK 057846-16, NIH P30 DK0636-08, WT212625/Z/18/Z, MR/R022259/1)
This publication has 55 references indexed in Scilit:
- The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearanceJournal of Clinical Investigation, 2013
- The Physiological Effects of Deleting the Mouse Slc30a8 Gene Encoding Zinc Transporter-8 Are Influenced by Gender and Genetic BackgroundPLOS ONE, 2012
- INS GFP/w human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cellsDiabetologia, 2011
- β-Cell Loss and β-Cell Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid DepositionThe American Journal of Pathology, 2011
- Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in miceProceedings of the National Academy of Sciences, 2009
- Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretionBiochemical Journal, 2009
- Insulin Storage and Glucose Homeostasis in Mice Null for the Granule Zinc Transporter ZnT8 and Studies of the Type 2 Diabetes–Associated VariantsDiabetes, 2009
- The immune system and the impact of zinc during agingImmunity & Ageing, 2009
- Chapter 16 Insulin Granule Biogenesis, Trafficking and Exocytosis2009
- The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetesProceedings of the National Academy of Sciences, 2007